On January 4, 2022, Mr. Timothy Jones, the Chief Executive Officer of RespireRx Pharmaceuticals Inc. notified the Company of his intent to resign which he and the Company subsequently agreed would target January 31, 2022 and would include his resignation as a member of the BOD. The BOD intends to appoint Arnold S. Lippa as Interim Chief Executive effective upon Mr. Jones' departure.